Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...

Notably, the compound demonstrates a broad therapeutic index and strong binding affinity to the MEK-RAF complex, offering potential advantages over existing MAPK inhibitors. Preclinical studies ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...